A Safety and Efficacy Study Evaluating CTX112 in Subjects With Refractory Neurologic Autoimmune Disease
← catalyst calendarNCT07804004 · readout in 1,212 d
Sponsored by CRISPR Therapeutics (industry) · CRSP — their whole pipeline →.
Phase
Phase 1/2
Status
Not yet recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
220estimated
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-09-04
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-09-15 | estimated | When the study began enrolling |
| Primary completion | 2029-12-30 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2029-12-30 | estimated | The whole study's end, after follow-up |
| First posted | 2026-09-04 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-09-04 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Progressive Multiple Sclerosis (PMS)
- Neuromyelitis Optica
- Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease
- Autoimmune Encephalitis
- Stiff-Person Syndrome
Intervention
- Biological: CTX112 — also filed as Zugocabtagene geleucel, zugo-cel
Primary outcome
what the primary-completion date above is the date OFTo evaluate the safety of CTX112 in adult participants with neurological autoimmue disorders, including PMS, relapsing NMOSD, relapsing MOGAD, refractory AIE, and refractory SPS.
measured From CTX112 infusion up to 28 days post infusion
Related
CRSP's other studiesmost recently updated first
- A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease Phase 1 · Recruiting
- A Trial Evaluating Safety, Tolerability and Efficacy of CTX340 in Participants With Hypertension Phase 1/2 · Recruiting
- A Safety and Tolerability Trial Evaluating CTX310 in Participants With Refractory Dyslipidemias Phase 1 · Recruiting
- Safety and Preliminary Efficacy of CTX112 in Adult Participants With Relapsed/Refractory Hematologic Autoimmune Disease Phase 1/2 · Recruiting
- An Open-Label, FIH Study Evaluating the Safety, Tolerability, and Efficacy of VCTX211 Combination Product in Subjects With T1D Phase 1 · Terminated
Permalink · CRSP's whole pipeline · Catalyst calendar · Every registered study · What changed